Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercial

Set Alert for Commercial

Roche To Build RWE Cancer Data Extraction Role With Flatiron Buy

Acquisition reflects that regulatory-grade real-world evidence will play increasing role in drug discovery, development, commercialization and reimbursement.

Business Strategies Commercial Digital Health

Novartis Sale Of US Oral Generics Unit Seems Unlikely

The Swiss giant's Sandoz division is exploring options for its underperforming US oral generics unit but reports that it may be considering a sale of the latter go against Novartis' previous comments and observers are struggling to see the rationale behind such a move.

Generic Drugs M & A Biosimilars
Advertisement

Companies

Set Alert for Companies

Latest From Companies

Jobs Go At Shield Therapeutics As Failed Study Fallout Hits

Shield Therapeutics is to slash its workforce and is considering a possible sale in the wake of a failed Phase III study for its only marketed product, Ferracru, that should have given it access to the US market.

Companies Commercial

Think Positive: Clovis Confident Of CHMP Okay For Rubraca

The US biotech expects to finally get its PARP inhibitor for ovarian cancer onto the European market in the next few months to compete with rivals AstraZeneca and Tesaro after the CHMP "communicated a positive trend vote" ahead of an opinion being issued next month.

Cancer Drug Review

Momentum At Indian Innovation Start-Ups: Will Pharma Take Notice?

Several Indian startups - many with overseas links - appear to be taking a shot at developing, among others, novel treatments targeting multi-drug resistant infections, biobetters and personalized cell based therapy. Funding, though, hasn’t been easy, according to one biopharma advisory firm.

Commercial Companies

Appointments: Changes At Hikma, Bluebird Bio, Celgene, Alkermes, Cell Medica, Editas Medicine, Futura Medical, Corline Biomedical And Horizon Discovery

Pharma and biotech appointments this week include a new CEO at Hikma and an interim-CEO at Horizon Discovery, a Chief Commercial Officer for bluebird bio, and new board directors at Celgene, Alkermes, Editas Medicine, and Futura Medical.

Appointments Companies

Waking Up Market To US Obstructive Sleep Apnea Epidemic

RespireRx president & CEO James Manuso explained to Scrip during the 2018 Biotech Showcase how the company is repurposing an existing drug to tackle the problem of sleep apnea.

Clinical Trials Companies

Strides' Net Profit Dives But Regulated Markets Seen Delivering Growth

Strides Shasun has reported third-quarter net profit plunged by 57% but the Indian firm says performance will improve in coming quarters thanks to its regulated market focus, and analysts agree earnings look set to rise.
Commercial Companies
See All

Deals

Set Alert for Deals

Latest From Deals

Gilead Partners With Sangamo For Gene Editing As It Builds Up Kite's Cell Therapy Platform

Gilead committed more than $3bn via its subsidiary Kite to license Sangamo's zinc finger technology for gene editing that may deliver improved T cell therapies for cancer. More deals are expected in this space as Gilead builds its cell therapy platform after buying Kite last year.
Deals Business Strategies

Preparing Emerging Biotechs For The Best Deals – Insider Insights

As the market for pharma and biotech deal making heats up in 2018, Scrip looks at the process of valuing novel companies with emerging data and collects best advice from experts on how start-ups should pitch to potential pharma partners.

Business Strategies Deals

Kolmar Korea Eyes Pharma Expansion Via CJ HealthCare Acquisition

The acquisition of mid-size South Korean pharma firm CJ HealthCare is set to boost Kolmar Korea's pharma business, enabling the cosmetics and pharma company to transform into a larger and more integrated healthcare firm.

Commercial Deals

Merck & Co's Viralytics Buy Puts Oncolytic Viruses Back In Spotlight

The US major is spending $394m to get hold of Cavatak, an immunotherapy that it hopes will work well in combination with the anti-PD-1 blockbuster Keytruda.

ImmunoOncology M & A

Takeda Catches Rising Tide Of Antisense Neuroscience R&D

Huntington's disease is one of several genetically defined neurological diseases that are being targeted in a multibillion-dollar collaboration forged between the US's Wave Life Sciences and Japan's Takeda, that could include co-commercialization by the biotech in the US.

Deals Neurology

AbbVie's Alzheimer's Efforts Voyage Into AAV-Targeted Tau Antibodies

Collaboration between Voyager and AbbVie will attempt to produce a single-administration gene therapy targeting tau protein, using adeno-associated vector technology to pass the blood-brain barrier.
Research & Development Deals
See All

Strategy

Set Alert for Strategy

Latest From Strategy

Jobs Go At Shield Therapeutics As Failed Study Fallout Hits

Shield Therapeutics is to slash its workforce and is considering a possible sale in the wake of a failed Phase III study for its only marketed product, Ferracru, that should have given it access to the US market.

Companies Commercial

Preparing Emerging Biotechs For The Best Deals – Insider Insights

As the market for pharma and biotech deal making heats up in 2018, Scrip looks at the process of valuing novel companies with emerging data and collects best advice from experts on how start-ups should pitch to potential pharma partners.

Business Strategies Deals

Waking Up Market To US Obstructive Sleep Apnea Epidemic

RespireRx president & CEO James Manuso explained to Scrip during the 2018 Biotech Showcase how the company is repurposing an existing drug to tackle the problem of sleep apnea.

Clinical Trials Companies

Can Sanofi’s Toujeo Prickle Tresiba In India?

Sanofi has launched its next generation basal insulin, Toujeo, on the Indian market at a significantly reduced per unit price point versus Novo Nordisk’s Tresiba (insulin degludec), setting the stage for an interesting market expansion battle.

India Pricing Strategies

Nektar/Bristol Deal May Shake Up Immuno-Oncology Landscape

The multibillion-dollar collaboration includes 20 studies, including two pivotal trials in renal cell carcinoma and non-small cell lung cancer that will start in the middle of the year.

Deals ImmunoOncology
See All

Market Access

Set Alert for Market Access

Latest From Market Access

AAD Roundup: Sun Sets Sights On Psoriasis As Competitive Pressures Mount

Sun presented new data on its IL-23 inhibitor tildrakizumab, pending US FDA approval, at the American Academy of Dermatology meeting. Novartis and others – all competing for payers' dollars – also try to make the case for their products.

Dermatology Research and Development Strategies

Mysterious Amazon/Berkshire/JPMorgan Partnership Could Disrupt Health Care, Pharma

The collective bargaining power of the three large employers, potentially assisted by Amazon's low-cost distribution channels, could be a formidable force in negotiating lower cost and better quality health care services, including pharmaceutical products.

Business Strategies Pricing Debate

Braeburn's Buprenorphine Bid: Eight Dosing Options Part Of "All Hands On Deck" Approach

With an FDA decision on its buprenorphine injection expected by Jan. 19, Scrip spoke with Braeburn executives at J.P. Morgan about the company's justification for four once-weekly and four once-monthly doses, competition in the opioid use disorder (OUD) market and the need for more OUD therapies.

Approvals Business Strategies
See All

Market Intelligence

Set Alert for Market Intelligence

Latest From Market Intelligence

Preparing Emerging Biotechs For The Best Deals – Insider Insights

As the market for pharma and biotech deal making heats up in 2018, Scrip looks at the process of valuing novel companies with emerging data and collects best advice from experts on how start-ups should pitch to potential pharma partners.

Business Strategies Deals

AAD Roundup: Sun Sets Sights On Psoriasis As Competitive Pressures Mount

Sun presented new data on its IL-23 inhibitor tildrakizumab, pending US FDA approval, at the American Academy of Dermatology meeting. Novartis and others – all competing for payers' dollars – also try to make the case for their products.

Dermatology Research and Development Strategies

AAD Roundup: More Data Emerges In Atopic Dermatitis, But Dupixent Maintains Big Lead

Atopic dermatitis (AD) was a hot topic at the AAD meeting based on last year's Dupixent approval and the growing array of new systemic and topical therapies for the skin condition – and the large market those products may address.

Clinical Trials Research and Development Strategies
See All
UsernamePublicRestriction

Register